• Explore /
  • Poster
  • / A phase III trial of capivasertib and abiraterone versus placebo and abiraterone in patients with <em>de novo</em> metastatic hormone-sensitive prostate cancer characterized by PTEN deficiency (CAPItello-281).

A phase III trial of capivasertib and abiraterone versus placebo and abiraterone in patients with de novo metastatic hormone-sensitive prostate cancer characterized by PTEN deficiency (CAPItello-281).

Abstract Video & Slides Poster

Authors

Karim Fizazi

Karim Fizazi

Institut Gustave Roussy and University of Paris Sud, Villejuif, France

Karim Fizazi , Daniel J. George , Maria De Santis , Noel Clarke , Andre P. Fay , Hirotsugu Uemura , Lynda Grinsted , Claire Rooney , Remy B Verheijen , Rana Anjum , Andrew Foxley , Thomas Morris

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 Genitourinary Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session: Advanced Prostate Cancer

Track

Prostate Cancer - Advanced

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT04493853

Citation

J Clin Oncol 39, 2021 (suppl 6; abstr TPS178)

DOI

10.1200/JCO.2021.39.6_suppl.TPS178

Abstract #

TPS178

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Simon J. Crabb

Poster

2023 ASCO Genitourinary Cancers Symposium

<span>Therapeutic effect of gedatolisib, a pan-PI3K/mTOR inhibitor, on prostate cancer models with PI3K or PTEN mutational status.</span>

Therapeutic effect of gedatolisib, a pan-PI3K/mTOR inhibitor, on prostate cancer models with PI3K or PTEN mutational status.

First Author: Adrish Sen

First Author: Adam McLain Kase

First Author: Christopher Sweeney